CN119656298A - 免疫刺激性组合物 - Google Patents
免疫刺激性组合物 Download PDFInfo
- Publication number
- CN119656298A CN119656298A CN202411608245.2A CN202411608245A CN119656298A CN 119656298 A CN119656298 A CN 119656298A CN 202411608245 A CN202411608245 A CN 202411608245A CN 119656298 A CN119656298 A CN 119656298A
- Authority
- CN
- China
- Prior art keywords
- immunostimulatory
- composition
- nucleic acid
- oligonucleotide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17207746 | 2017-12-15 | ||
| EP17207740 | 2017-12-15 | ||
| EP17207746.3 | 2017-12-15 | ||
| EP17207750 | 2017-12-15 | ||
| EP17207750.5 | 2017-12-15 | ||
| EP17207740.6 | 2017-12-15 | ||
| PCT/EP2018/083956 WO2019115385A1 (en) | 2017-12-15 | 2018-12-07 | Immunostimulatory compositions |
| CN201880089491.8A CN111801116B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性组合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880089491.8A Division CN111801116B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119656298A true CN119656298A (zh) | 2025-03-21 |
Family
ID=66818991
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411608245.2A Pending CN119656298A (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性组合物 |
| CN202510619819.4A Pending CN120519464A (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激寡核苷酸 |
| CN201880089469.3A Pending CN111801419A (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性寡核苷酸 |
| CN201880080814.7A Active CN111447949B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激寡核苷酸 |
| CN201880089491.8A Active CN111801116B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性组合物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510619819.4A Pending CN120519464A (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激寡核苷酸 |
| CN201880089469.3A Pending CN111801419A (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性寡核苷酸 |
| CN201880080814.7A Active CN111447949B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激寡核苷酸 |
| CN201880089491.8A Active CN111801116B (zh) | 2017-12-15 | 2018-12-07 | 免疫刺激性组合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US20210062192A1 (https=) |
| EP (4) | EP3700564B1 (https=) |
| JP (5) | JP7458977B2 (https=) |
| KR (4) | KR102787688B1 (https=) |
| CN (5) | CN119656298A (https=) |
| AU (5) | AU2018385257B2 (https=) |
| BR (2) | BR112020011815A2 (https=) |
| CA (3) | CA3085575A1 (https=) |
| CL (3) | CL2020001560A1 (https=) |
| CO (3) | CO2020007120A2 (https=) |
| CR (1) | CR20200260A (https=) |
| DK (1) | DK3700564T3 (https=) |
| DO (3) | DOP2020000106A (https=) |
| ES (1) | ES3052969T3 (https=) |
| IL (3) | IL274975A (https=) |
| MX (4) | MX2020006244A (https=) |
| PE (3) | PE20210635A1 (https=) |
| PH (3) | PH12020550906A1 (https=) |
| PL (1) | PL3700564T3 (https=) |
| SG (3) | SG11202004471RA (https=) |
| TW (3) | TWI821224B (https=) |
| UY (3) | UY38016A (https=) |
| WO (3) | WO2019115386A1 (https=) |
| ZA (1) | ZA202004317B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021007160A1 (en) | 2019-07-05 | 2021-01-14 | Tambo, Inc. | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
| WO2021154745A1 (en) * | 2020-01-27 | 2021-08-05 | Oregon State University | Gonorrhea subunit vaccine |
| CN113493790A (zh) | 2020-04-01 | 2021-10-12 | 南京华普生物技术股份有限公司 | 具有免疫调节功能的CpG ODN及其应用 |
| EP3892260A1 (en) * | 2020-04-10 | 2021-10-13 | Bayer Animal Health GmbH | Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids |
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| CN112159814B (zh) * | 2020-10-29 | 2023-05-16 | 中国农业科学院兰州兽医研究所 | 一种CpG寡聚脱氧核苷酸及制备与其用途 |
| CN113797329A (zh) * | 2021-10-19 | 2021-12-17 | 启锰生物科技(江苏)有限公司 | 一种二价锰佐剂和CpG佐剂的疫苗佐剂组合物及其制作方法 |
| CN116218852A (zh) * | 2023-02-22 | 2023-06-06 | 中国人民解放军陆军军医大学 | 一种靶向基因启动子G-四联体区域的sgRNA及其用途 |
| WO2025149000A1 (zh) * | 2024-01-09 | 2025-07-17 | 康希诺(上海)生物研发有限公司 | 一种免疫刺激序列截断多聚a尾的序列构建及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719028A (en) * | 1992-12-07 | 1998-02-17 | Third Wave Technologies Inc. | Cleavase fragment length polymorphism |
| EP1167379A3 (en) * | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| NZ517929A (en) | 1999-09-25 | 2004-02-27 | Univ Iowa Res Found | Immunostimulatory nucleic acids |
| AU783118B2 (en) * | 1999-09-27 | 2005-09-29 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
| KR100359753B1 (ko) * | 1999-12-21 | 2002-11-09 | 주식회사 제넥신 | 면역조절능력 및 안전성이 증가되고 ｄＧ 연속서열이결합된 포스포다이에스터 ＣｐＧ올리고데옥시뉴클레오티드 변형체 |
| WO2002002807A2 (en) | 2000-06-30 | 2002-01-10 | Epigenomics Ag | Diagnosis of diseases associated with cell signalling |
| AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
| MXPA05013658A (es) * | 2003-06-11 | 2006-03-02 | Hybridon Inc | Oligonucleotidos inmunomoduladores estabilizados. |
| AU2004275876B2 (en) | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| EP1678303A2 (en) * | 2003-10-30 | 2006-07-12 | Coley Pharmaceutical GmbH | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
| EP1680446B1 (en) * | 2003-11-05 | 2007-10-31 | Pevion Biotech Ltd. | Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens |
| CN1250737C (zh) * | 2003-11-07 | 2006-04-12 | 深圳市未来海洋科技发展有限公司 | 含CpG DNA畜禽疫苗佐剂的PCR制备方法 |
| KR100558851B1 (ko) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | 면역조절능력이 증가된 ＣｐＧ 올리고데옥시뉴클레오티드변형체 |
| CN1989439B (zh) * | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | 治疗葡萄膜炎的方法以及组合物 |
| US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
| EP1764108A1 (en) * | 2005-09-14 | 2007-03-21 | Gunther Hartmann | Compositions comprising immunostimulatory RNA oligonucleotides and methods for producing said RNA oligonucleotides |
| US8114636B2 (en) * | 2006-02-10 | 2012-02-14 | Life Technologies Corporation | Labeling and detection of nucleic acids |
| DK2405002T3 (en) | 2006-02-15 | 2015-01-05 | Adiutide Pharmaceuticals Gmbh | Compositions and methods for oligonukleotidformuleringer |
| CN100418583C (zh) * | 2006-02-21 | 2008-09-17 | 朱鸿飞 | 预防和治疗乳腺炎的药物组合物 |
| US20080124366A1 (en) | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
| CN101240271B (zh) * | 2006-08-28 | 2012-08-29 | 长春华普生物技术有限公司 | Toll样受体调节性寡核苷酸及其用途 |
| PT2078080E (pt) | 2006-09-27 | 2015-09-18 | Coley Pharm Gmbh | Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada |
| KR20100045508A (ko) | 2007-08-13 | 2010-05-03 | 콜리 파마슈티칼 게엠베하 | 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프 |
| WO2010129672A1 (en) | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
| WO2010130374A1 (en) * | 2009-05-14 | 2010-11-18 | Bayer Animal Health Gmbh | Enhanced immune response in avian species |
| EP2575878B1 (en) | 2010-05-28 | 2018-06-13 | Zoetis Belgium S.A. | Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules |
| CN101979542B (zh) * | 2010-10-28 | 2011-12-28 | 国家兽用生物制品工程技术研究中心 | 含CpG基序的核酸序列的制备方法及应用 |
| BR112013016231B1 (pt) | 2010-12-22 | 2021-03-23 | Bayer Intellectual Property Gmbh | Composição imunomoduladora para o tratamento de doença respiratória bovina |
| EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
| PL2714908T3 (pl) * | 2011-05-26 | 2018-07-31 | Intervet International B.V. | Oligodeoksynukleotydy immunostymulacyjne |
| MX346596B (es) * | 2011-05-26 | 2017-03-23 | Intervet Int Bv | Oligodesoxinucleotidos inmunoestimuladores. |
| JP6375289B2 (ja) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫刺激組成物およびその使用方法 |
| AR091569A1 (es) * | 2012-06-28 | 2015-02-11 | Intervet Int Bv | Receptores de tipo toll |
| WO2014082083A1 (en) * | 2012-11-26 | 2014-05-30 | Caris Science, Inc. | Biomarker compositions and methods |
| US9506030B2 (en) | 2013-05-01 | 2016-11-29 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| CN112263675B (zh) * | 2013-07-19 | 2024-02-27 | 财团法人卫生研究院 | CpG寡脱氧核苷酸、包含其的免疫组合物及制备组合物并通过其刺激免疫反应的方法 |
| AR097029A1 (es) * | 2013-07-26 | 2016-02-17 | Intervet Int Bv | Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune |
| GB2517700A (en) * | 2013-08-27 | 2015-03-04 | Lgc Ltd | Oligonucleotides comprising a secondary structure and uses thereof |
| KR20160122849A (ko) | 2014-02-28 | 2016-10-24 | 바이엘 애니멀 헬스 게엠베하 | 면역자극성 플라스미드 |
| US10888603B2 (en) * | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
-
2018
- 2018-12-07 CR CR20200260A patent/CR20200260A/es unknown
- 2018-12-07 EP EP18829225.4A patent/EP3700564B1/en active Active
- 2018-12-07 PL PL18829225.4T patent/PL3700564T3/pl unknown
- 2018-12-07 MX MX2020006244A patent/MX2020006244A/es unknown
- 2018-12-07 CN CN202411608245.2A patent/CN119656298A/zh active Pending
- 2018-12-07 WO PCT/EP2018/083958 patent/WO2019115386A1/en not_active Ceased
- 2018-12-07 EP EP18811581.0A patent/EP3701032A1/en active Pending
- 2018-12-07 CA CA3085575A patent/CA3085575A1/en active Pending
- 2018-12-07 EP EP25202362.7A patent/EP4647437A3/en active Pending
- 2018-12-07 PE PE2020000765A patent/PE20210635A1/es unknown
- 2018-12-07 JP JP2020531988A patent/JP7458977B2/ja active Active
- 2018-12-07 CN CN202510619819.4A patent/CN120519464A/zh active Pending
- 2018-12-07 US US16/771,789 patent/US20210062192A1/en not_active Abandoned
- 2018-12-07 DK DK18829225.4T patent/DK3700564T3/da active
- 2018-12-07 SG SG11202004471RA patent/SG11202004471RA/en unknown
- 2018-12-07 SG SG11202004773SA patent/SG11202004773SA/en unknown
- 2018-12-07 ES ES18829225T patent/ES3052969T3/es active Active
- 2018-12-07 KR KR1020207020349A patent/KR102787688B1/ko active Active
- 2018-12-07 CA CA3085661A patent/CA3085661A1/en active Pending
- 2018-12-07 AU AU2018385257A patent/AU2018385257B2/en active Active
- 2018-12-07 KR KR1020207020350A patent/KR20200099556A/ko active Pending
- 2018-12-07 CN CN201880089469.3A patent/CN111801419A/zh active Pending
- 2018-12-07 AU AU2018382419A patent/AU2018382419B2/en active Active
- 2018-12-07 AU AU2018385256A patent/AU2018385256B2/en active Active
- 2018-12-07 CN CN201880080814.7A patent/CN111447949B/zh active Active
- 2018-12-07 WO PCT/EP2018/083956 patent/WO2019115385A1/en not_active Ceased
- 2018-12-07 JP JP2020531982A patent/JP7770769B2/ja active Active
- 2018-12-07 MX MX2020006246A patent/MX2020006246A/es unknown
- 2018-12-07 PE PE2020000767A patent/PE20200933A1/es unknown
- 2018-12-07 EP EP18829227.0A patent/EP3694549A1/en active Pending
- 2018-12-07 CA CA3085657A patent/CA3085657A1/en active Pending
- 2018-12-07 CN CN201880089491.8A patent/CN111801116B/zh active Active
- 2018-12-07 BR BR112020011815-0A patent/BR112020011815A2/pt unknown
- 2018-12-07 SG SG11202004952UA patent/SG11202004952UA/en unknown
- 2018-12-07 US US16/772,541 patent/US11932857B2/en active Active
- 2018-12-07 WO PCT/EP2018/084019 patent/WO2019115402A1/en not_active Ceased
- 2018-12-07 PE PE2020000766A patent/PE20210636A1/es unknown
- 2018-12-07 KR KR1020257009617A patent/KR20250048594A/ko active Pending
- 2018-12-07 MX MX2020006243A patent/MX2020006243A/es unknown
- 2018-12-07 JP JP2020531972A patent/JP7273040B2/ja active Active
- 2018-12-07 BR BR112020011838-9A patent/BR112020011838A2/pt unknown
- 2018-12-07 KR KR1020207020351A patent/KR20200098638A/ko not_active Ceased
- 2018-12-07 US US16/772,046 patent/US11542507B2/en active Active
- 2018-12-13 TW TW107144947A patent/TWI821224B/zh active
- 2018-12-13 TW TW107144948A patent/TWI900461B/zh active
- 2018-12-13 TW TW107144946A patent/TWI911138B/zh active
- 2018-12-14 UY UY0001038016A patent/UY38016A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038015A patent/UY38015A/es not_active Application Discontinuation
- 2018-12-14 UY UY0001038014A patent/UY38014A/es not_active Application Discontinuation
-
2020
- 2020-05-27 IL IL274975A patent/IL274975A/en unknown
- 2020-06-03 IL IL275086A patent/IL275086A/en unknown
- 2020-06-08 IL IL275217A patent/IL275217A/en unknown
- 2020-06-10 DO DO2020000106A patent/DOP2020000106A/es unknown
- 2020-06-10 DO DO2020000113A patent/DOP2020000113A/es unknown
- 2020-06-10 DO DO2020000107A patent/DOP2020000107A/es unknown
- 2020-06-11 CL CL2020001560A patent/CL2020001560A1/es unknown
- 2020-06-11 CL CL2020001561A patent/CL2020001561A1/es unknown
- 2020-06-11 CO CONC2020/0007120A patent/CO2020007120A2/es unknown
- 2020-06-11 CO CONC2020/0007100A patent/CO2020007100A2/es unknown
- 2020-06-11 CL CL2020001562A patent/CL2020001562A1/es unknown
- 2020-06-11 CO CONC2020/0007102A patent/CO2020007102A2/es unknown
- 2020-06-15 PH PH12020550906A patent/PH12020550906A1/en unknown
- 2020-06-15 PH PH12020550903A patent/PH12020550903A1/en unknown
- 2020-06-15 PH PH12020550904A patent/PH12020550904A1/en unknown
- 2020-07-13 MX MX2025007909A patent/MX2025007909A/es unknown
- 2020-07-14 ZA ZA2020/04317A patent/ZA202004317B/en unknown
-
2022
- 2022-08-08 US US17/883,031 patent/US12305173B2/en active Active
- 2022-11-18 US US18/057,053 patent/US20230332162A1/en active Pending
-
2023
- 2023-08-07 JP JP2023128316A patent/JP2023153970A/ja active Pending
- 2023-08-07 US US18/366,306 patent/US20240076681A1/en active Pending
- 2023-08-21 JP JP2023134080A patent/JP7760560B2/ja active Active
-
2025
- 2025-01-31 US US19/043,004 patent/US20250215439A1/en active Pending
- 2025-06-20 AU AU2025204678A patent/AU2025204678A1/en active Pending
- 2025-07-03 AU AU2025205082A patent/AU2025205082A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111801116B (zh) | 免疫刺激性组合物 | |
| EP2658974B1 (en) | Immunostimulatory oligodeoxynucleotides | |
| US20050256073A1 (en) | Immunostimulatory viral RNA oligonucleotides | |
| EP1872786A1 (en) | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation | |
| AU2021230501A1 (en) | Coronavirus vaccines comprising a TLR9 agonist | |
| HK40039985A (en) | Immunostimulatory compositions | |
| BR122024026586A2 (pt) | Uso de plasmídeo de ácido nucleico e veículo de entrega de lipossomo e oligonucleotídeo imunoestimulatório com motivo de cpg e sequência de oligonucleotídeo enriquecida por guanina na terminação 5' | |
| BR112020011845B1 (pt) | Composições imunoestimulatórias e método de preparação das mesmas | |
| HK40039984A (en) | Immunostimulatory oligonucleotides | |
| RU2795701C2 (ru) | Иммуностимулирующие олигонуклеотиды | |
| HK1029515B (en) | Use of immunostimulatory oligonucleotides for preventing or treating asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |